Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly nab-paclitaxel + carboplatin with concurrent thoracic radiotherapy in elderly patients with unresectable stage III non-small-cell lung cancer
jRCTs042180077Phase 1Completed
- Start
- Nov 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel and carboplatin in non-small cell lung cancer (NSCLC). Primary endpoints: Frequency of dose-limiting toxicity and Treatment completion rate. Started Nov 2014; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs042180077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs042180077.